Media headlines about Cancer Genetics (NASDAQ:CGIX) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cancer Genetics earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.0594565479771 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several brokerages have weighed in on CGIX. HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a report on Tuesday. ValuEngine raised Cancer Genetics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Maxim Group set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a report on Wednesday, December 13th. Finally, Zacks Investment Research raised Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $5.56.
Shares of Cancer Genetics (NASDAQ CGIX) traded down $0.10 during midday trading on Thursday, reaching $1.80. The company’s stock had a trading volume of 102,832 shares, compared to its average volume of 161,731. The firm has a market cap of $50.56, a PE ratio of -2.20 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a 52-week low of $1.70 and a 52-week high of $5.30.
In other Cancer Genetics news, Director John Pappajohn purchased 150,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were bought at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the purchase, the director now owns 2,781,204 shares in the company, valued at approximately $5,173,039.44. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 21.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cancer Genetics (CGIX) Stock Price” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://sportsperspectives.com/2018/02/08/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cancer-genetics-cgix-stock-price.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.